To help define the most important corporate responsibility (CR) issues for Novartis, the company completed a CR materiality analysis in 2013. The term “CR materiality” is a measure of how important CR issues are to the company and our stakeholders.
We interviewed nearly 100 stakeholders inside and outside the company to help us assess a wide range of economic, ethical, social, environmental and governance issues. We use these findings to guide our strategy, track issues of concern, inform and prioritize our corporate responsibility programs, and establish meaningful metrics against which to measure our performance.
In 2015, we conducted a review of our materiality analysis with our external stakeholders. This confirmed the results of our 2013 exercise, encouraging us to further focus on access to healthcare, governance and ethical business practices, and research and development in 2016.